<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">mrj</journal-id><journal-title-group><journal-title xml:lang="ru">Современная ревматология</journal-title><trans-title-group xml:lang="en"><trans-title>Modern Rheumatology Journal</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">1996-7012</issn><issn pub-type="epub">2310-158X</issn><publisher><publisher-name>IMA-PRESS, LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.14412/1996-7012-2025-3-87-93</article-id><article-id custom-type="elpub" pub-id-type="custom">mrj-1779</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОРИГИНАЛЬНЫЕ ИССЛЕДОВАНИЯ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>ORIGINAL INVESTIGATIONS</subject></subj-group></article-categories><title-group><article-title>Удовлетворенность своим состоянием пациентов с ревматоидным артритом, по данным дистанционной оценки: пилотное исследование ОПТИМА (Оценка Пациентами Тяжести, Исходов и Медицинской помощи при Артрите)</article-title><trans-title-group xml:lang="en"><trans-title>Patient satisfaction with health status in rheumatoid arthritis based on remote assessment: a pilot OPTIMA study (Patient-reported Outcomes, Severity and Medical care in Arthritis)</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0001-5103-5447</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Полищук</surname><given-names>Е. Ю.</given-names></name><name name-style="western" xml:lang="en"><surname>Polishchuk</surname><given-names>E. Yu.</given-names></name></name-alternatives><bio xml:lang="ru"><p>Елена Юрьевна Полищук </p><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>Elena Yuryevna Polishchuk </p><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><email xlink:type="simple">dr.pogozheva@mail.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-1391-0711</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Каратеев</surname><given-names>А. Е.</given-names></name><name name-style="western" xml:lang="en"><surname>Karateev</surname><given-names>A. E.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-3583-9442</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Махмудов</surname><given-names>Х. Р.</given-names></name><name name-style="western" xml:lang="en"><surname>Makhmudov</surname><given-names>H. R.</given-names></name></name-alternatives><bio xml:lang="ru"><p>734003, Душанбе, проспект Рудаки, 139 </p></bio><bio xml:lang="en"><p>139, Rudaki Prospect, Dushanbe 734003 </p></bio><xref ref-type="aff" rid="aff-2"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0009-0005-6115-7612</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Калашников</surname><given-names>К. С.</given-names></name><name name-style="western" xml:lang="en"><surname>Kalashnikov</surname><given-names>K. S.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p></bio><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Булгакова</surname><given-names>Н. А.</given-names></name><name name-style="western" xml:lang="en"><surname>Bulgakova</surname><given-names>N. A.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115516, Москва, ул. Промышленная, 11, стр. 3 </p></bio><bio xml:lang="en"><p>11, Promyshlennaya Street, Build. 3, Moscow 115516 </p></bio><xref ref-type="aff" rid="aff-3"/></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid">https://orcid.org/0000-0002-6068-3080</contrib-id><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лила</surname><given-names>А. М.</given-names></name><name name-style="western" xml:lang="en"><surname>Lila</surname><given-names>A. M.</given-names></name></name-alternatives><bio xml:lang="ru"><p>115522, Москва, Каширское шоссе, 34А </p><p>125993, Москва, ул. Баррикадная, 2/1, стр. 1 </p></bio><bio xml:lang="en"><p>34A, Kashirskoye Shosse, Moscow, 115522 </p><p>2/1, Barrikadnaya Street, Build. 1, 125993 Moscow </p></bio><xref ref-type="aff" rid="aff-4"/></contrib></contrib-group><aff-alternatives id="aff-1"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-2"><aff xml:lang="ru"><institution>Таджикский государственный медицинский университет им. Абуали ибни Сино</institution><country>Таджикистан</country></aff><aff xml:lang="en"><institution>Avicenna Tajik State Medical University</institution><country>Tajikistan</country></aff></aff-alternatives><aff-alternatives id="aff-3"><aff xml:lang="ru"><institution>Общероссийская общественная организация инвалидов «Российская ревматологическая ассоциация «Надежда»</institution><country>Россия</country></aff><aff xml:lang="en"><institution>All-Russian Non-profit Organization of disabled people “Russian Rheumatological Association “Nadezhda”</institution><country>Russian Federation</country></aff></aff-alternatives><aff-alternatives id="aff-4"><aff xml:lang="ru"><institution>ФГБНУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» ; ФГБОУ ДПО «Российская медицинская академия непрерывного профессионального образования» Минздрава России</institution><country>Россия</country></aff><aff xml:lang="en"><institution>V.A. Nasonova Research Institute of Rheumatology ; Russian Medical Academy of Continuing Professional Education</institution><country>Russian Federation</country></aff></aff-alternatives><pub-date pub-type="collection"><year>2025</year></pub-date><pub-date pub-type="epub"><day>24</day><month>06</month><year>2025</year></pub-date><volume>19</volume><issue>3</issue><fpage>87</fpage><lpage>93</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Полищук Е.Ю., Каратеев А.Е., Махмудов Х.Р., Калашников К.С., Булгакова Н.А., Лила А.М., 2025</copyright-statement><copyright-year>2025</copyright-year><copyright-holder xml:lang="ru">Полищук Е.Ю., Каратеев А.Е., Махмудов Х.Р., Калашников К.С., Булгакова Н.А., Лила А.М.</copyright-holder><copyright-holder xml:lang="en">Polishchuk E.Y., Karateev A.E., Makhmudov H.R., Kalashnikov K.S., Bulgakova N.A., Lila A.M.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://mrj.ima-press.net/mrj/article/view/1779">https://mrj.ima-press.net/mrj/article/view/1779</self-uri><abstract><p>Ведущие российские и мировые эксперты признают необходимость включения в динамический контроль состояния больных ревматоидным артритом (РА) параметров, оцениваемых самим пациентом (ПОСП). Интегральным показателем общего самочувствия и удовлетворенности лечением является состояние симптомов, приемлемое для пациента (ССПП).Цель исследования – определить удовлетворенность пациентов с РА своим самочувствием и результатами лечения, а также ее взаимосвязь с основными проявлениями болезни с помощью дистанционной оценки ПОСП.Материал и методы. С января 2023 г. по ноябрь 2024 г. проведен онлайн-опрос 2115 пациентов с РА (88,3% женщины, средний возраст – 46,4±13,9 года, медиана длительности болезни – 6 [3; 13] лет), в ходе которого оценивались демографические показатели, терапия, ССПП, ПОСП (боль, усталость, тревога, депрессия, повседневная активность, общая оценка состояния здоровья пациентом – ОСЗП – по числовой рейтинговой шкале – ЧРШ, от 0 до 10). 80% опрошенных получали синтетические базисные противовоспалительные препараты, 23,8% – генно-инженерные биологические препараты (ГИБП) и ингибиторы Янус-киназ (иJAK). Глюкокортикоиды (ГК) применяли 39,7%, нестероидные противовоспалительные препараты (НПВП) – 67,9% больных.Результаты и обсуждение. Положительную оценку своему состоянию (ССПП+) дали 45,8% пациентов. Боль по ЧРШ составила в среднем 5,6±2,7, усталость – 6,2±2,7, ОСЗП – 5,5±2,5, медиана тревоги – 5 [3; 8], депрессии – 5 [2; 7], ограничения повседневной активности – 5 [3; 7]. Неудовлетворенность своим состоянием (ССПП-) ассоциировалась с мужским полом, умеренной (≥4) или высокой (≥7) интенсивностью ПОСП по ЧРШ, а также с приемом ГК и НПВП. Терапия ГИБП и иJAK показала обратную связь с ССПП-. С помощью бинарной логистической регрессии была сформирована модель, позволяющая прогнозировать ССПП- у больных РА с точностью до 71%. При анализе ROC-кривых пороговое значение логистической функции P составило 49,6%, площадь под кривой – 0,740 (95% доверительный интервал 0,718–0,762), чувствительность модели – 82%, специфичность – 60%.Заключение. При дистанционной оценке меньше половины пациентов с РА были удовлетворены состоянием своего здоровья. ССПП имеет четкую взаимосвязь с ПОСП и может быть интегральным показателем состояния здоровья и удовлетворенности терапией РА.</p></abstract><trans-abstract xml:lang="en"><p>Leading Russian and international experts recognize the necessity of incorporating patient-reported outcomes (PROs) into the dynamic monitoring of rheumatoid arthritis (RA) patients. An integral indicator of general well-being and treatment satisfaction is the Patient Acceptable Symptom State (PASS).Objective: To assess patient satisfaction with their health status and treatment outcomes in RA and to evaluate its relationship with key disease manifestations through remote PROs assessment.Material and methods. From January 2023 to November 2024, an online survey was conducted involving 2,115 RA patients (88.3% women, mean age 46.4±13.9 years, median disease duration 6 [3; 13] years). The survey assessed demographics, therapy, PASS, and PROs (pain, fatigue, anxiety, depression, daily activity limitations, patient global assessment [PGA], using a numerical rating scale [NRS], 0–10). Among respondents, 80% were receiving conventional synthetic disease-modifing antirheumatic drugs (DMARDs), 23.8% biologic DMARDs (bDMARDs) or Janus kinase inhibitors (JAKi). Glucocorticoids (GCs) were used by 39.7%, and nonsteroidal anti-inflammatory drugs (NSAIDs ) by 67.9% of patients.Results and discussion. A positive assessment of their health status (PASS+) was reported by 45.8% of patients. Mean NRS scores were: pain – 5.6±2.7, fatigue – 6.2±2.7, PGA – 5.5±2.5, median anxiety – 5 [3; 8], depression – 5 [2; 7], daily activity limitations – 5 [3; 7]. Dissatisfaction (PASS-) was associated with male gender, moderate (≥4) or high (≥7) NRS PRO scores, and the use of GCs and NSAIDs. bDMARD and JAKi therapy showed an inverse association with PASS-. A binary logistic regression model was developed to predict PASS- in RA patients with an accuracy of up to 71%. ROC curve analysis revealed a threshold value of the logistic function P at 49.6%, area under the curve (AUC) – 0.740 (95% CI 0.718–0.762), model sensitivity – 82%, specificity – 60%.Conclusion. Fewer than half of RA patients were satisfied with their health status when assessed remotely. PASS is closely associated with PROs and may serve as an integral indicator of health status and treatment satisfaction in RA.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>ревматоидный артрит</kwd><kwd>дистанционная оценка</kwd><kwd>состояние симптомов</kwd><kwd>приемлемое для пациента</kwd><kwd>параметры</kwd><kwd>оцениваемые самим пациентом</kwd><kwd>боль</kwd><kwd>усталость</kwd><kwd>ограничение повседневной активности</kwd><kwd>депрессия</kwd><kwd>тревога</kwd></kwd-group><kwd-group xml:lang="en"><kwd>rheumatoid arthritis</kwd><kwd>remote assessment</kwd><kwd>patient acceptable symptom state</kwd><kwd>patient-reported outcomes</kwd><kwd>pain</kwd><kwd>fatigue</kwd><kwd>daily activity limitation</kwd><kwd>depression</kwd><kwd>anxiety</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">Van Tuyl LH, Sadlonova M, Hewlett S, et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis. 2017 May; 76(5):855-861. doi: 10.1136/annrheumdis-2016-209835. Epub 2016 Nov 30.</mixed-citation><mixed-citation xml:lang="en">Van Tuyl LH, Sadlonova M, Hewlett S, et al. The patient perspective on absence of disease activity in rheumatoid arthritis: a survey to identify key domains of patient-perceived remission. Ann Rheum Dis. 2017 May; 76(5):855-861. doi: 10.1136/annrheumdis-2016-209835. Epub 2016 Nov 30.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Michaud K, Pope J, van de Laar M, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthrtis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-1616. doi: 10.1002/acr.24369. Epub 2021 Sep 9.</mixed-citation><mixed-citation xml:lang="en">Michaud K, Pope J, van de Laar M, et al. Systematic Literature Review of Residual Symptoms and an Unmet Need in Patients With Rheumatoid Arthrtis. Arthritis Care Res (Hoboken). 2021 Nov;73(11):1606-1616. doi: 10.1002/acr.24369. Epub 2021 Sep 9.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Ishida M, Kuroiwa Y, Yoshida E, et al. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Mod Rheumatol. 2018 Sep;28(5): 789-799. doi: 10.1080/14397595.2017.1416940. Epub 2018 Jan 11.</mixed-citation><mixed-citation xml:lang="en">Ishida M, Kuroiwa Y, Yoshida E, et al. Residual symptoms and disease burden among patients with rheumatoid arthritis in remission or low disease activity: a systematic literature review. Mod Rheumatol. 2018 Sep;28(5): 789-799. doi: 10.1080/14397595.2017.1416940. Epub 2018 Jan 11.</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Ishiguro N, Dougados M, Cai Z, et al. Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. Mod Rheumatol. 2018 Nov;28(6):950-959. doi: 10.1080/14397595.2017.1422232. Epub 2018 Feb 2.</mixed-citation><mixed-citation xml:lang="en">Ishiguro N, Dougados M, Cai Z, et al. Relationship between disease activity and patient-reported outcomes in rheumatoid arthritis: Post hoc analyses of overall and Japanese results from two phase 3 clinical trials. Mod Rheumatol. 2018 Nov;28(6):950-959. doi: 10.1080/14397595.2017.1422232. Epub 2018 Feb 2.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Исходы лечения, оцениваемые самим пациентом, – новая философия анализа эффективности терапии при иммуновоспалительных заболеваниях. Современная ревматология. 2021;15(5):121-127. doi: 10.14412/1996-7012-2021-5-121-127</mixed-citation><mixed-citation xml:lang="en">Patient's reported outcomes – a new philosophy for analyzing the effectiveness of therapy in immunoinflammatory diseases. Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2021;15(5):121-127. (In Russ.). doi: 10.14412/1996-7012-2021-5-121-127</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007 May;34(5):1188-93.</mixed-citation><mixed-citation xml:lang="en">Tubach F, Ravaud P, Beaton D, et al. Minimal clinically important improvement and patient acceptable symptom state for subjective outcome measures in rheumatic disorders. J Rheumatol. 2007 May;34(5):1188-93.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Puyraimond-Zemmour D, Etcheto A, Fautrel B, et al. Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1504-1509. doi: 10.1002/acr.23176. Epub 2017 Sep 6.</mixed-citation><mixed-citation xml:lang="en">Puyraimond-Zemmour D, Etcheto A, Fautrel B, et al. Associations Between Five Important Domains of Health and the Patient Acceptable Symptom State in Rheumatoid Arthritis and Psoriatic Arthritis: A Cross-Sectional Study of 977 Patients. Arthritis Care Res (Hoboken). 2017 Oct;69(10):1504-1509. doi: 10.1002/acr.23176. Epub 2017 Sep 6.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012 Nov; 64(11):1699-707. doi: 10.1002/acr.21747.</mixed-citation><mixed-citation xml:lang="en">Tubach F, Ravaud P, Martin-Mola E, et al. Minimum clinically important improvement and patient acceptable symptom state in pain and function in rheumatoid arthritis, ankylosing spondylitis, chronic back pain, hand osteoarthritis, and hip and knee osteoarthritis: Results from a prospective multinational study. Arthritis Care Res (Hoboken). 2012 Nov; 64(11):1699-707. doi: 10.1002/acr.21747.</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Salaffi F, Carotti M, Gutierrez M, et al. Patient Acceptable Symptom State in SelfReport Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care. Biomed Res Int. 2015; 2015:930756. doi: 10.1155/2015/930756. Epub 2015 Jun 18.</mixed-citation><mixed-citation xml:lang="en">Salaffi F, Carotti M, Gutierrez M, et al. Patient Acceptable Symptom State in SelfReport Questionnaires and Composite Clinical Disease Index for Assessing Rheumatoid Arthritis Activity: Identification of Cut-Off Points for Routine Care. Biomed Res Int. 2015; 2015:930756. doi: 10.1155/2015/930756. Epub 2015 Jun 18.</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Safikhani M, Rezaieyazdi Z, Khodashahi M. Evaluation of assessable telemedicine in patients with rheumatoid arthritis: A systematic review. Int J Rheum Dis. 2024 Jan;27(1): e15007. doi: 10.1111/1756-185X.15007.</mixed-citation><mixed-citation xml:lang="en">Safikhani M, Rezaieyazdi Z, Khodashahi M. Evaluation of assessable telemedicine in patients with rheumatoid arthritis: A systematic review. Int J Rheum Dis. 2024 Jan;27(1): e15007. doi: 10.1111/1756-185X.15007.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Arumalla N, Chan CKD, Gibson M, et al. The clinical impact of electronic patient-reported outcome measures in the remote monitoring of inflammatory arthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 2023 Nov;75(11):1892-1903. doi: 10.1002/art.42559. Epub 2023 Sep 18.</mixed-citation><mixed-citation xml:lang="en">Arumalla N, Chan CKD, Gibson M, et al. The clinical impact of electronic patient-reported outcome measures in the remote monitoring of inflammatory arthritis: a systematic review and meta-analysis. Arthritis Rheumatol. 2023 Nov;75(11):1892-1903. doi: 10.1002/art.42559. Epub 2023 Sep 18.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">Barlas N, Barlas SB, Basnyat S, Adalier E. Telemedicine in Rheumatoid Arthritis: A Review of the PubMed Literature. Mediterr J Rheumatol. 2023 Mar 31;34(1):16-23. doi: 10.31138/mjr.34.1.16.</mixed-citation><mixed-citation xml:lang="en">Barlas N, Barlas SB, Basnyat S, Adalier E. Telemedicine in Rheumatoid Arthritis: A Review of the PubMed Literature. Mediterr J Rheumatol. 2023 Mar 31;34(1):16-23. doi: 10.31138/mjr.34.1.16.</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">Потапова АС, Каратеев АЕ, Полищук ЕЮ и др. Центральная сенситизация снижает удовлетворенность своим состоянием пациентов с ревматоидным артритом. Данные проспективного исследования. Научно-практическая ревматология. 2024;62(5):535-541.</mixed-citation><mixed-citation xml:lang="en">Potapova AS, Karateev AE, Polishchuk EYu, et al. Central sensitization reduces the satisfaction of patients with rheumatoid arthritis. The data of prospective study. Nauchno-prakticheskaya revmatologiya. 2024;62(5):535-541. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">Heiberg T, Kvien TK, Mowinckel P, et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Jul;67(7):967-71. doi: 10.1136/ard.2007.077503. Epub 2007 Oct 26.</mixed-citation><mixed-citation xml:lang="en">Heiberg T, Kvien TK, Mowinckel P, et al. Identification of disease activity and health status cut-off points for the symptom state acceptable to patients with rheumatoid arthritis. Ann Rheum Dis. 2008 Jul;67(7):967-71. doi: 10.1136/ard.2007.077503. Epub 2007 Oct 26.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Katchamart W, Narongroeknawin P, Suppa-Udom B, et al. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020 Mar;39(3):779-786. doi: 10.1007/s10067-019-04860-3. Epub 2019 Dec 10.</mixed-citation><mixed-citation xml:lang="en">Katchamart W, Narongroeknawin P, Suppa-Udom B, et al. Factors associated with and cutoff points for Patient Acceptable Symptom State (PASS) in rheumatoid arthritis. Clin Rheumatol. 2020 Mar;39(3):779-786. doi: 10.1007/s10067-019-04860-3. Epub 2019 Dec 10.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Полищук ЕЮ, Потапова АС, Амирджанова ВН. Маленький секрет большой ревматологии. Научно-практическая ревматология. 2024;62(4):335-341.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Polishchuk EYu, Potapova AS, Amirdzhanova VN. A small secret of big rheumatology. Nauchno-Prakticheskaya Revmatologia. 2024;62(4):335-341. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Каратеев АЕ, Полищук ЕЮ, Потапова АС и др. Результаты назначения генноинженерных биологических препаратов и ингибиторов Янус-киназ при ревматоидном артрите в период пандемии коронавирусной болезни COVID-19: данные телефонного опроса 254 пациентов. Научно-практическая ревматология. 2022;60(2): 149-156.</mixed-citation><mixed-citation xml:lang="en">Karateev AE, Polishchuk EYu, Potapova AS, et al. The use of biological disease-modifying antirheumatic drugs and Janus kinase inhibitors in rheumatoid arthritis during the COVID-19 coronavirus disease pandemic: data from a telephone survey of 254 patients. Nauchno-prakticheskaya revmatologiya. 2022; 60(2):149-156. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2010 Jan; 37(1):26-31. doi: 10.3899/jrheum.090449. Epub 2009 Dec 1.</mixed-citation><mixed-citation xml:lang="en">Kvamme MK, Kristiansen IS, Lie E, Kvien TK. Identification of cutpoints for acceptable health status and important improvement in patient-reported outcomes, in rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. J Rheumatol. 2010 Jan; 37(1):26-31. doi: 10.3899/jrheum.090449. Epub 2009 Dec 1.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Воробьева ЛД, Коротаева ТВ, Логинова ЕЮ и др. Влияние тофацитиниба на оценку состояния здоровья по мнению пациентов с псориатическим артритом. Данные реальной практики. Научно-практическая ревматология. 2022;60(3):334-340.</mixed-citation><mixed-citation xml:lang="en">Vorobyeva LD, Korotaeva TV, Loginova EYu, et al. Impact of tofacitinib on patient-reported outcomes in patients with psoriatic arthritis. Data from the real clinical practice. Nauchnoprakticheskaya revmatologiya. 2022;60(3): 334-340. (In Russ.).</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Gwinnutt JM, Hyrich KL, Lunt M, et al. RAMS Co-Investigators. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'. Rheumatology (Oxford). 2020 Aug 1;59(8):1853-1861. doi: 10.1093/rheumatology/kez497.</mixed-citation><mixed-citation xml:lang="en">Gwinnutt JM, Hyrich KL, Lunt M, et al. RAMS Co-Investigators. Long-term outcomes of patients who rate symptoms of rheumatoid arthritis as 'satisfactory'. Rheumatology (Oxford). 2020 Aug 1;59(8):1853-1861. doi: 10.1093/rheumatology/kez497.</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Duarte C, Santos E, Kvien TK, et al. Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021 Jan;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003. Epub 2020 Sep 10.</mixed-citation><mixed-citation xml:lang="en">Duarte C, Santos E, Kvien TK, et al. Attainment of the Patient-acceptable Symptom State in 548 patients with rheumatoid arthritis: Influence of demographic factors. Joint Bone Spine. 2021 Jan;88(1):105071. doi: 10.1016/j.jbspin.2020.09.003. Epub 2020 Sep 10.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Stocker PH, Jasper MH, Kahlow B, et al. Depression as a major determinant of PASS (Patient's Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022 Aug;68(8):995-999. doi: 10.1590/1806-9282.20220600.</mixed-citation><mixed-citation xml:lang="en">Stocker PH, Jasper MH, Kahlow B, et al. Depression as a major determinant of PASS (Patient's Acceptable Symptoms State) in rheumatoid arthritis: a cross-sectional study in Brazilian patients. Rev Assoc Med Bras (1992). 2022 Aug;68(8):995-999. doi: 10.1590/1806-9282.20220600.</mixed-citation></citation-alternatives></ref><ref id="cit23"><label>23</label><citation-alternatives><mixed-citation xml:lang="ru">Garufi C, Mancuso S, Ceccarelli F, et al. PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1725. Epub 2024 Nov 5.</mixed-citation><mixed-citation xml:lang="en">Garufi C, Mancuso S, Ceccarelli F, et al. PASSing to the patient side: early achieving of an acceptable symptom state in patients with rheumatoid arthritis treated with Janus kinase inhibitors. Reumatismo. 2025 Feb 13;77(1). doi: 10.4081/reumatismo.2024.1725. Epub 2024 Nov 5.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
